SG11202105465WA - 2-fluorinated bile acids for the treatment of neurodegenerative diseases - Google Patents
2-fluorinated bile acids for the treatment of neurodegenerative diseasesInfo
- Publication number
- SG11202105465WA SG11202105465WA SG11202105465WA SG11202105465WA SG11202105465WA SG 11202105465W A SG11202105465W A SG 11202105465WA SG 11202105465W A SG11202105465W A SG 11202105465WA SG 11202105465W A SG11202105465W A SG 11202105465WA SG 11202105465W A SG11202105465W A SG 11202105465WA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- neurodegenerative diseases
- bile acids
- fluorinated
- fluorinated bile
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1820887.6A GB201820887D0 (en) | 2018-12-20 | 2018-12-20 | Compounds |
| PCT/GB2019/053665 WO2020128514A1 (en) | 2018-12-20 | 2019-12-20 | 2-fluorinated bile acids for the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105465WA true SG11202105465WA (en) | 2021-06-29 |
Family
ID=65364420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105465WA SG11202105465WA (en) | 2018-12-20 | 2019-12-20 | 2-fluorinated bile acids for the treatment of neurodegenerative diseases |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220073557A1 (en) |
| EP (1) | EP3898645A1 (en) |
| JP (1) | JP2022514401A (en) |
| KR (1) | KR20210125982A (en) |
| CN (1) | CN113330020B (en) |
| AU (1) | AU2019411556A1 (en) |
| BR (1) | BR112021011189A2 (en) |
| CA (1) | CA3123333A1 (en) |
| EA (1) | EA202191521A1 (en) |
| GB (1) | GB201820887D0 (en) |
| IL (1) | IL284093A (en) |
| MX (1) | MX2021007551A (en) |
| SG (1) | SG11202105465WA (en) |
| WO (1) | WO2020128514A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202208151D0 (en) | 2022-06-01 | 2022-07-13 | Nzp Uk Ltd | Compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2934596B1 (en) * | 2008-07-30 | 2015-04-10 | Trophos | NOVEL CHOLEST-4-EN-3-ONE OXIME DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND PROCESS FOR PREPARING THE SAME |
| WO2014036379A2 (en) * | 2012-08-31 | 2014-03-06 | Metselex | Bile acids prevent or abolish progression of parkinson's and related neurodegenerative diseases |
| US20150112089A1 (en) | 2013-10-22 | 2015-04-23 | Metselex, Inc. | Deuterated bile acids |
| WO2016145216A1 (en) | 2015-03-10 | 2016-09-15 | Metselex, Inc. | Fluorinated and alkylated bile acids |
-
2018
- 2018-12-20 GB GBGB1820887.6A patent/GB201820887D0/en not_active Ceased
-
2019
- 2019-12-20 CN CN201980085276.5A patent/CN113330020B/en active Active
- 2019-12-20 MX MX2021007551A patent/MX2021007551A/en unknown
- 2019-12-20 CA CA3123333A patent/CA3123333A1/en active Pending
- 2019-12-20 AU AU2019411556A patent/AU2019411556A1/en active Pending
- 2019-12-20 BR BR112021011189-1A patent/BR112021011189A2/en unknown
- 2019-12-20 US US17/415,216 patent/US20220073557A1/en active Pending
- 2019-12-20 SG SG11202105465WA patent/SG11202105465WA/en unknown
- 2019-12-20 WO PCT/GB2019/053665 patent/WO2020128514A1/en unknown
- 2019-12-20 EA EA202191521A patent/EA202191521A1/en unknown
- 2019-12-20 JP JP2021535715A patent/JP2022514401A/en active Pending
- 2019-12-20 EP EP19831850.3A patent/EP3898645A1/en active Pending
- 2019-12-20 KR KR1020217019166A patent/KR20210125982A/en unknown
-
2021
- 2021-06-16 IL IL284093A patent/IL284093A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019411556A1 (en) | 2021-06-10 |
| KR20210125982A (en) | 2021-10-19 |
| US20220073557A1 (en) | 2022-03-10 |
| JP2022514401A (en) | 2022-02-10 |
| BR112021011189A2 (en) | 2021-08-31 |
| CA3123333A1 (en) | 2020-06-25 |
| CN113330020B (en) | 2024-04-05 |
| IL284093A (en) | 2021-08-31 |
| EA202191521A1 (en) | 2021-09-10 |
| CN113330020A (en) | 2021-08-31 |
| WO2020128514A1 (en) | 2020-06-25 |
| EP3898645A1 (en) | 2021-10-27 |
| MX2021007551A (en) | 2021-10-13 |
| GB201820887D0 (en) | 2019-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3600309T1 (en) | Therapeutic combinations for treating liver diseases | |
| IL254288B (en) | C22-, c23- and c24-amino-carbonyl-oxy derivatives of bile acids and their use for treating tgr5-mediated diseases | |
| EP3227330A4 (en) | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases | |
| IL265902A (en) | Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases | |
| IL269106A (en) | Methods of treating neurodegenerative diseases | |
| SG11202006374VA (en) | Treatment of demyelinating diseases | |
| ZA201805407B (en) | Composition for the prevention or treatment of neurodegenerative diseases. | |
| ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
| EP3856243A4 (en) | Methods of treating neurodegenerative diseases | |
| ZA202101587B (en) | Protein for treatment of inflammatory diseases | |
| EP3634394A4 (en) | Compositions for treating neurodegenerative diseases | |
| GB201714307D0 (en) | Treatment of neurodegenerative diseases | |
| IL284093A (en) | 2-fluorinated bile acids for the treatment of neurodegenerative diseases | |
| IL273929A (en) | Therapeutic agents for neurodegenerative diseases | |
| EP3283457A4 (en) | Compounds and methods for the treatment of neurodegenerative diseases | |
| EP3829560A4 (en) | Compounds for the treatment of neurological or mitochondrial diseases | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| EP3534954A4 (en) | Compounds for treatment of neurodegenerative diseases | |
| IL282360A (en) | Treatment of neurological diseases | |
| IL280441A (en) | Sulfopropanoic acid derivatives for treating neurodegenerative disorders | |
| KR102324922B9 (en) | Pharmaceutical composition comprising osteocalcin for preventing or treating inflammatory diseases | |
| EP3846816A4 (en) | Neuroprotective agents for treatment of neurodegenerative diseases | |
| HUE058268T2 (en) | Ursodeoxycholic acid derivatives for the treatment of polycystic diseases | |
| FI3752173T3 (en) | Combination of rhodiola and astragalus for the treatment of neurodegenerative diseases | |
| EP3755334A4 (en) | Treatment of liver diseases |